Omeprazole (A2845): Technical Guide for Gastric Acid Secretion Research

What This Product Solves

Omeprazole (SKU A2845) is a well-characterized H+,K+-ATPase inhibitor that enables precise modulation of gastric acid secretion in laboratory models. Researchers leverage its inhibitory selectivity and potency—documented by an IC₅₀ of 5.8 μM against H+,K+-ATPase and 0.16 μM against histamine-induced acid formation—to dissect the mechanisms of acid secretion, antiulcer activity, and peptic ulcer disease. Its chemical structure, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, and high DMSO solubility (≥17.27 mg/mL) make it particularly suitable for controlled, non-aqueous experimental protocols.

Omeprazole is intended solely for scientific research. It is not formulated for diagnostic, clinical, or therapeutic workflows, and its insolubility in water and ethanol precludes use in aqueous-based assays. Applications include preclinical gastric acid secretion research, antiulcer activity studies, and modeling of gastric acid-related disorders.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition
  Value: IC₅₀ = 5.8 μM
  Applicability: Use as a reference inhibitor in ATPase activity assays.
  Rationale: Defines potency for benchmarking and comparative studies.
  Source type: product information
• Assay: Histamine-stimulated gastric acid formation
  Value: IC₅₀ = 0.16 μM
  Applicability: Dose selection for in vitro gastric acid secretion models.
  Rationale: Supports establishment of concentration-response relationships in antiulcer activity studies.
  Source type: product information
• Assay: Solubility in DMSO
  Value: ≥17.27 mg/mL
  Applicability: Stock solution preparation for non-aqueous protocols.
  Rationale: Enables precise dosing and reproducibility in peptic ulcer disease models and related workflows.
  Source type: product information
• Assay: Storage condition
  Value: Solid at -20°C; avoid long-term solution storage
  Applicability: Ensures compound stability across experimental campaigns.
  Rationale: Maintains purity and activity for reproducible results.
  Source type: product information

Workflow Setup and QC Checklist

To ensure reliable outcomes in gastric acid secretion research using Omeprazole (A2845), rigorous workflow setup and quality control are essential:

• Compound Handling: Upon receipt, verify blue ice shipping and immediately transfer the solid to -20°C storage. Confirm the integrity of the container and desiccant to prevent moisture uptake.
• Stock Preparation: Dissolve Omeprazole in DMSO to the required concentration (≤17.27 mg/mL), using calibrated pipettes and pre-dried glassware. Vortex thoroughly and confirm complete dissolution visually—undissolved material may impact assay accuracy.
• Aliquoting: Prepare small, single-use aliquots to minimize freeze-thaw cycles. Discard any unused solution after one use; do not store diluted stocks for extended periods, as per the product’s stability profile.
• Purity Check: Each batch is provided at ~98% purity. If internal quality control is required, use HPLC or LC-MS to confirm integrity before use in critical assays.
• Documentation: Record lot number, preparation date, and storage logs for traceability across experimental series.

For additional context on protocol setup and troubleshooting, researchers may reference the internal article "Omeprazole (A2845): Protocols for Gastric Acid Secretion Research", which details laboratory workflows and controls for this compound.

Common Failure Modes and Fixes

• Incomplete Dissolution: If Omeprazole does not fully dissolve in DMSO, gently warm the solution (≤37°C) while vortexing. Ensure DMSO is anhydrous; water contamination reduces solubility and may precipitate the compound.
• Loss of Potency: Avoid repeated freeze-thaw cycles and prolonged solution storage. Always use freshly prepared stocks for critical experiments.
• Assay Interference: Due to its insolubility in water and ethanol, avoid introducing Omeprazole directly into aqueous systems. Pre-dilute in DMSO and, if necessary, further dilute into compatible non-aqueous media.
• Batch Variability: Cross-validate new lots using a reference standard or internal control. Document any deviations from expected IC₅₀ values and adjust experimental baselines accordingly.

Researchers seeking comparative troubleshooting strategies may consult "3-(quinolin-4-ylmethylamino) Thiophene-2-Carboxamide: Advanced Protocols and Troubleshooting", which provides additional guidance for antiulcer activity studies.

Scope and Limitations

• Intended Use: Omeprazole (A2845) is strictly for research purposes and is not validated for diagnostic or therapeutic applications.
• Solubility Constraints: Its insolubility in water and ethanol limits its use to DMSO-based or compatible non-aqueous workflows. Do not attempt to use in protocols requiring direct aqueous delivery.
• Storage: Only the solid form is recommended for long-term storage; solution forms are unstable and should be prepared fresh as needed.
• Species/Model Restrictions: Use in non-mammalian or poorly characterized models may require additional pilot validation, as workflow guidance is based on established preclinical protocols.

Conclusion

Omeprazole (A2845) from APExBIO offers researchers a reproducible, high-purity H+,K+-ATPase inhibitor for targeted studies in gastric acid secretion and antiulcer activity. By strictly adhering to solubility, storage, and handling parameters, researchers can ensure robust data in preclinical and mechanistic workflows. For compound details, batch-specific data, and ordering, visit Omeprazole. Implementation of best practices as outlined above supports consistent outcomes in gastric acid-related disorder models and antiulcer research.